Cargando…
Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352671/ https://www.ncbi.nlm.nih.gov/pubmed/34438245 http://dx.doi.org/10.1016/j.ejca.2021.07.040 |
| _version_ | 1783736234171957248 |
|---|---|
| author | Malissen, Nausicaa Ninove, Laetitia de Lamballerie, Xavier André, Nicolas Gaudy-Marqueste, Caroline |
| author_facet | Malissen, Nausicaa Ninove, Laetitia de Lamballerie, Xavier André, Nicolas Gaudy-Marqueste, Caroline |
| author_sort | Malissen, Nausicaa |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8352671 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83526712021-08-10 Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population Malissen, Nausicaa Ninove, Laetitia de Lamballerie, Xavier André, Nicolas Gaudy-Marqueste, Caroline Eur J Cancer Letter to the Editor Elsevier Ltd. 2021-10 2021-08-10 /pmc/articles/PMC8352671/ /pubmed/34438245 http://dx.doi.org/10.1016/j.ejca.2021.07.040 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Malissen, Nausicaa Ninove, Laetitia de Lamballerie, Xavier André, Nicolas Gaudy-Marqueste, Caroline Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population |
| title | Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population |
| title_full | Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population |
| title_fullStr | Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population |
| title_full_unstemmed | Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population |
| title_short | Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population |
| title_sort | safety and immunogenicity after 2 doses of the bnt162b2 covid-19 vaccine in an early-phase oncology trial centre population |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352671/ https://www.ncbi.nlm.nih.gov/pubmed/34438245 http://dx.doi.org/10.1016/j.ejca.2021.07.040 |
| work_keys_str_mv | AT malissennausicaa safetyandimmunogenicityafter2dosesofthebnt162b2covid19vaccineinanearlyphaseoncologytrialcentrepopulation AT ninovelaetitia safetyandimmunogenicityafter2dosesofthebnt162b2covid19vaccineinanearlyphaseoncologytrialcentrepopulation AT delamballeriexavier safetyandimmunogenicityafter2dosesofthebnt162b2covid19vaccineinanearlyphaseoncologytrialcentrepopulation AT andrenicolas safetyandimmunogenicityafter2dosesofthebnt162b2covid19vaccineinanearlyphaseoncologytrialcentrepopulation AT gaudymarquestecaroline safetyandimmunogenicityafter2dosesofthebnt162b2covid19vaccineinanearlyphaseoncologytrialcentrepopulation |